Prevacid I.V. Related Published Studies
Well-designed clinical trials related to Prevacid I.V. (Lansoprazole)
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. [2008.04]
Clinical response to 2 dosing regimens of lansoprazole in infants with gastroesophageal reflux. [2008.03]
Initial treatment with lansoprazole in young dyspeptic patients with negative urea breath test result: a randomized controlled trial with 12-month follow-up. [2007.07]
Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. [2007.05]
Effect of Helicobacter pylori infection and acid blockade by lansoprazole on clarithromycin bioavailability. [2007.03]
Acid control with esomeprazole and lansoprazole: a comparative dose-response study. [2007.02]
Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. [2007.01.15]
Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. [2006.10]
Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection. [2006.10]
A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease. [2006.07]
Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. [2006.07]
Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve. [2006.06]
Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. [2006.04.15]
Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages. [2006.04.01]
Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h. [2006.04.01]
Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. [2006.02.01]
Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole. [2006.02]
Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: A comparison between two different daily doses of lansoprazole. [2006.01.07]
Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole. [2006.01]
Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. [2006.01]
Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers. [2006]
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. [2005.11]
Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg. [2005.10.01]
Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. [2005.09]
A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease. [2005.07.15]
Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status. [2005.07.01]
Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry. [2005.07]
Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. [2005.07]
Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine. [2005.06]
Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes. [2005.06]
Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. [2005.05]
Helicobacter pylori eradication using tetracycline and furazolidone versus amoxicillin and azithromycin in lansoprazole based triple therapy: an open randomized clinical trial. [2005.04]
Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. [2005.03]
Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. [2005.02.15]
Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori. [2004.12]
Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. [2004.12]
Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. [2004.11]
Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis. [2004.10.15]
Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection. [2004.07.31]
Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. [2001.07]
Well-designed clinical trials possibly related to Prevacid I.V. (Lansoprazole)
Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy. [2008.01]
Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. [2007.12]
Failures in a proton pump inhibitor therapeutic substitution program: lessons learned. [2007.10]
Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. [2007.08]
Improvement in symptoms after H(2)-receptor antagonist-based therapy for eradication of H pylori infection. [2007.07.28]
High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. [2007.06]
Effects of uptake and efflux transporter inhibition on erythromycin breath test results. [2007.06]
Proton pump inhibitors: effective first-line treatment for management of dyspepsia. [2007.04]
Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. [2007.04]
Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan. [2007.03]
Effects of anti-Helicobacter pylori treatment and probiotic supplementation on intestinal microbiota. [2007.01]
High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. [2007]
A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover study. [2006.11.15]
Prospective trial of laparoscopic nissen fundoplication versus proton pump inhibitor therapy for gastroesophageal reflux disease: Seven-year follow-up. [2006.11]
Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. [2006.09.01]
The effect of CYP2C19 substrate on the metabolism of melatonin in the elderly: A randomized, double-blind, placebo-controlled study. [2006.09]
Pharmacoeconomic comparison of Helicobacter pylori eradication regimens. [2006.08]
Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double-blind study. [2006.07]
Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori Infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area. [2006.06]
Design and planned analyses of an ongoing randomized trial assessing the preventive effect of Helicobacter pylori eradication on occurrence of new gastric carcinomas after endoscopic resection. [2006.06]
Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial. [2006.03.21]
Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. [2006.02]
Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. [2006.01]
Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study. [2006.01]
Optimal maintenance therapy in patients with non-erosive reflux disease reporting mild reflux symptoms--a pilot study. [2006]
Effect of Clostridium butyricum on fecal flora in Helicobacter pylori eradication therapy. [2005.12.21]
Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study. [2005.12]
A randomized trial of triple therapy for pediatric Helicobacter pylori infection and risk factors for treatment failure in a population with a high prevalence of infection. [2005.11.01]
Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura. [2005.11]
Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. [2005.11]
The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. [2005.09.15]
Management of symptoms in step-down therapy of gastroesophageal reflux disease. [2005.09]
Dipyridamole bioavailability in subjects with reduced gastric acidity. [2005.07]
Quality of gastric ulcer healing evaluated by endoscopic ultrasonography. [2005.06.14]
Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. [2005.05.15]
Efficacy of triple therapy plus cetraxate for the Helicobacter pylori eradication in partial gastrectomy patients. [2005.05]
[Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office] [2005.04.07]
First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens. [2005.03.15]
Effects of killing Helicobacter pylori quadruple therapy on peptic ulcer: a randomized double-blind clinical trial. [2005.02.21]
Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. [2005.02.15]
Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers. [2005.01]
Treatment with proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding: a meta-analysis. [2005.01]
Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. [2004.10]
The influence of pretreatment on cure rates of Helicobacter pylori eradication. [2004.06]
Other research related to Prevacid I.V. (Lansoprazole)
Linear mucosal defect may be characteristic of lansoprazole-associated collagenous colitis. [2008.06]
Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole. [2008.05.28]
Comparison of enteral and intravenous lansoprazole pharmacodynamic response in critically ill patients. [2008.05.03]
Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers. [2008.05]
Stronger inhibition of gastric acid secretion by lafutidine, a novel H(2) receptor antagonist, than by the proton pump inhibitor lansoprazole. [2008.04.21]
Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers. [2008.04.07]
Acute interstitial nephritis related to lansoprazole administration. [2008.04]
Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults. [2008.03.15]
Greater Immediate Gastric Acid Suppression with Lansoprazole 30 mg Administered as a 2-Minute Intravenous Bolus Injection versus a 30-Minute Infusion. [2008.03]
Reversible lansoprazole-induced interstitial lung disease showing improvement after drug cessation. [2008.03]
Pharmacological compliance and acceptability of lansoprazole orally disintegrating tablets in primary care. [2008.02]
Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. [2008.02]
Age-dependent pharmacokinetics of lansoprazole in neonates and infants. [2008]
Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year. [2008]
Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg in controlling intragastric acidity in healthy adults. [2007.12.19]
Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. [2007.10]
Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. [2007.09.01]
|
